Sugi Predict

Sugi Predict / Compounds / SCHEMBL870522

SCHEMBL870522

SCHEMBL870522

Cc1ccc2nc(CO)cn2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.50
▸ RAB9A P51151 6/20 0.50
▸ KDM4E B2RXH2 6/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ PAX8 Q06710 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ MITF O75030 1/20 0.50
▸ KDM5A P29375 1/20 0.50
▸ KDM5C P41229 1/20 0.50
▸ PKM P14618 2/20 0.46
▸ TP53 P04637 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ TSHR P16473 1/20 0.46
▸ CDK5 Q00535 1/20 0.46
▸ CDK5R1 Q15078 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ APP P05067 2/20 0.45
▸ POLB P06746 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633339 0.82 NPC1 (0.52) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL9570490 0.81 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL23530863 0.81 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL8174291 0.81 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL22499393 0.79 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL22499245 0.79 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL13572991 0.79 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL871183 0.79 GRM5 (0.47) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL9598420 0.79 KDM4E (0.63) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2
SCHEMBL14758258 0.79 MCHR1 (0.42) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2025-12-25 — — US disclosed
US-12358915-B2 METTL3 inhibitory compounds STORM Therapeutics Ltd. (GB) 2025-07-15 — — US disclosed
WO-2024059186-A1 N-((ISOQUINOLIN-6-YL)METHYL)-1H-PYRAZOLE-4-CARBOXAMID DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-03-21 — — WO disclosed
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LIMITED (GB) 2023-03-16 — — US disclosed
EP-3946618-A1 METTL3 INHIBITORY COMPOUNDS Storm Therapeutics Ltd (GB) 2022-02-09 — — EP disclosed
CN-113905787-A METTL3 inhibiting compounds 斯托姆治疗有限公司 2022-01-07 — — CN disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 — — WO disclosed
WO-2020201773-A1 METTL3 INHIBITORY COMPOUNDS STORM THERAPEUTICS LTD (GB) 2020-10-08 — — WO disclosed
US-9273017-B2 (Thio)morpholine derivatives as S1P modulators ABBVIE BAHAMAS LIMITED (BS) 2016-03-01 — — US disclosed
US-9273017-B2 (Thio)morpholine derivatives as S1P modulators ABBVIE BAHAMAS LIMITED (BS) 2016-03-01 — — US disclosed
US-20100204203-A1 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors ALCON RESEARCH, LTD. 2010-08-12 — — US disclosed
US-20100204203-A1 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors ALCON RESEARCH, LTD. 2010-08-12 — — US disclosed
US-20100204203-A1 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors ALCON RESEARCH, LTD. 2010-08-12 — — US disclosed
EP-2106396-A2 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS AstraZeneca AB (SE) 2009-10-07 — — EP disclosed
US-20090124596-A1 Chemical Compounds 637 ALCON RESEARCH, LTD. 2009-05-14 — — US disclosed
US-20090124596-A1 Chemical Compounds 637 ALCON RESEARCH, LTD. 2009-05-14 — — US disclosed
US-20090124596-A1 Chemical Compounds 637 ALCON RESEARCH, LTD. 2009-05-14 — — US disclosed
WO-2008084223-A2 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS ASTRAZENECA AB (SE) 2008-07-17 — — WO disclosed
WO-2008084223-A2 CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS ASTRAZENECA AB (SE) 2008-07-17 — — WO disclosed
US-5270322-A Imidazo[1,2-a]pyridines, pharmaceutical compositions containing these compounds and processes for preparing them DR. KARL THOMAE GMBH (DE) 1993-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12358915-B2 METTL3 inhibitory compounds METTL3, METTL16, DIMT1 NPC1 2030/4885RAB9A 1839/4885KDM4E 62/4885
US-20250388577-A1 METTL3 INHIBITORY COMPOUNDS METTL3, RNMT, TPMT NPC1 418/4885RAB9A 1986/4885KDM4E 717/4885
US-20090124596-A1 Chemical Compounds 637 PDE4A, PDE4B, PDE3B NPC1 2462/4885RAB9A 1736/4885KDM4E 1494/4885
US-20100204203-A1 Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors PDE4A, PDE4B, PDE5A NPC1 3510/4885RAB9A 1730/4885KDM4E 525/4885
US-20230085408-A1 METTL3 INHIBITORY COMPOUNDS METTL3, METTL16, DIMT1 NPC1 2030/4885RAB9A 1839/4885KDM4E 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.